Abstract
Despite multiple therapeutic modalities, treatment of atopic dermatitis with its chronic, relapsing nature remains a challenge. Chronic use of standard therapies is associated with variable efficacy and potential side effects. Targeted therapeutic approaches using biologic agents may prove to be a novel alternative. We present a case of severe recalcitrant atopic dermatitis successfully treated with efalizumab.
MeSH terms
-
Adult
-
Antibodies, Monoclonal / immunology
-
Antibodies, Monoclonal / pharmacology
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Humanized
-
CD11 Antigens / immunology
-
Dermatitis, Atopic / drug therapy*
-
Dermatitis, Atopic / immunology
-
Drug Resistance
-
Female
-
Follow-Up Studies
-
Humans
-
Treatment Outcome
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
CD11 Antigens
-
efalizumab